RxDoctor Payments Data

Anthony Klappa, MD

Interventional Cardiology · Springdale, ARNPI 1982998837

Payments from drug & device makers

What this record shows

The money is spread across several categories — grants (45.6%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Abbott accounts for 69.2% of it on its own, with 21 other manufacturers making up the rest. Reporting peaked in 2020 at $10,231 and has fallen 93.9% since, to $621 in 2025.

$21,951in general payments, 2019–2025

Across 115 payments — averaging $190.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$15K
  • Inari Medical, Inc.$3K
  • Abiomed$2K
  • Medtronic$633
  • BD$373
  • Biotronik Inc.$207
  • plus $802 from 16 others

What the payments were for

  • Speaking & faculty fees$3732%
  • Grants$10,00046%
  • Travel & lodging$5,64526%
  • Food & beverage$5,92227%
  • Education$110%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$21,951 in reported general payments places this provider in the 85th percentile of 89 interventional cardiology providers in Arkansas.

See all interventional cardiology providers in Arkansas

Medicare billing

Part B allowed, 2024
$126,173
Medicare patients
604
Services billed
1,771

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban132$128,316
XareltoRivaroxaban51$56,122
EntrestoSacubitril/Valsartan37$56,114
JardianceEmpagliflozin14$16,872
FarxigaDapagliflozin Propanediol12$15,407
Repatha SureclickEvolocumab11$6,252
Atorvastatin Calcium276$2,354
Metoprolol Succinate115$1,365
ClopidogrelClopidogrel Bisulfate145$1,342
Losartan Potassium146$1,331
Diltiazem 24hr Er (Cd)Diltiazem Hcl38$1,224
Carvedilol116$859
SotalolSotalol Hcl31$818
Midodrine Hcl15$728
Amlodipine Besylate134$653

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$107$128,316132 claims
Johnson & JohnsonXarelto$35$56,12251 claims
NovartisEntresto$12$56,11437 claims
Boehringer IngelheimJardiance$24$16,87214 claims
AstraZenecaFarxiga$17$15,40712 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 89 interventional cardiology providers in Arkansas.

Other interventional cardiology in Springdale

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →